| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |